Screen Readers Skip to Content
Tweet Facebook Email
Print Page

Needle-free HPV Vaccine Increases Effectiveness and Availability

Author: American Association of Pharmaceutical Scientists

Published: Thursday, 18th November 2010 (9 years ago) - Updated: Thursday, 18th November 2010 (9 years ago) .

Synopsis:

Targeted inhalable dry powder vaccine may replace current commercial human papillomavirus (HPV) vaccine used throughout the world.

Main Digest

New needle-free HPV vaccine increases effectiveness, availability in developing world.

New research being presented at the 2010 FIP Pharmaceutical Sciences World Congress in association with the American Association of Pharmaceutical Scientists Annual Meeting and Exposition will highlight a targeted inhalable dry powder vaccine that may prove preferable in terms of needle avoidance and expected lower cost than the current commercial human papillomavirus (HPV) vaccine used throughout the world.

HPV is the number one cause of cervical cancer, which is the second most common cancer in women around the globe. According to the World Health Organization, nearly a quarter of a million women die each year from cervical cancer, 80 percent of them in developing countries.

Lead researcher David McAdams and colleagues from the University of Colorado at Boulder created a dry powder that goes directly to the mucous membranes in the respiratory tract or mouth. Since HPV is a disease that affects the mucous membranes, the powder is more targeted. "Imagine the vaccine as a car," said McAdams. "Using this delivery method is similar to parking in your driveway instead of driving around the block a few times to find a spot."

The dry powder has added benefits for developing countries. For example, the current HPV vaccine is delivered by a needle injection, which is highly susceptible to contamination. The powder, as a solid, rather than a frozen liquid, may be more stable than current HPV vaccines, which makes it easier to store and transport in developing countries.

"While there are effective HPV vaccines on the market, cost, refrigeration and needle disposal shorten the reach they have," commented McAdams. "Our goal is to develop an economical, safe and easily administered HPV vaccine for everyone."

For the first time, FIP's PSWC and the AAPS Annual Meeting and Exposition will join to hold the world's largest pharmaceutical sciences meeting to improve global health through advances in pharmaceutical sciences. An estimated 10,000 scientists from more than 60 countries will participate in 100 sessions, including 40 symposia and round-tables.

Learn more about the meeting and global health from leading scientists in this Webisode series and follow the tweet hashtag #PSWC2010 for meeting updates.

About AAPS: The American Association of Pharmaceutical Scientists is a professional, scientific society of approximately 12,000 members employed in academia, industry, government and other research institutes worldwide. For more information, please visit www.aapspharmaceutica.com

About FIP: The International Pharmaceutical Federation is the global federation of national associations representing two million pharmacists and pharmaceutical scientists from around the world. For more information, please visit www.fip.org

Similar Documents

For further related information see our full list of Immunization Documents.

If you use an RSS feed reader you are welcome to subscribe to our latest Immunization publications.

Important Disclaimer:
Disabled World is strictly a news and information website provided for general informational purpose only and does not constitute medical advice. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World.

Please report 📧 outdated or inaccurate information to us.